DCM
ACRS icon

Driehaus Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Driehaus Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-250,484
Closed -$1.85M – 390
2018
Q4 		$1.85M Sell
250,484
-252,512
-50% -$2.6M 0.08% 231
2018
Q3 		$7.3M Sell
502,996
-82,212
-14% -$1.41M 0.22% 140
2018
Q2 		$11.7M Sell
585,208
-5,968
-1% -$110K 0.4% 71
2018
Q1 		$10.4M Buy
591,176
+67,748
+13% +$1.44M 0.37% 63
2017
Q4 		$12.9M Buy
523,428
+222,254
+74% +$5.41M 0.49% 44
2017
Q3 		$7.77M Buy
301,174
+25,564
+9% +$685K 0.3% 84
2017
Q2 		$7.47M Sell
275,610
-55,587
-17% -$1.51M 0.27% 80
2017
Q1 		$9.88M Sell
331,197
-136,740
-29% -$3.94M 0.34% 66
2016
Q4 		$12.7M Buy
467,937
+285,002
+156% +$7.27M 0.45% 40
2016
Q3 		$4.68M Buy
+182,935
New +$3.88M 0.16% 134

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Driehaus Capital Management's ACRS Position: Q1 2019 in Review

Driehaus Capital Management sold out of Aclaris Therapeutics (ACRS) in Q1 2019, closing a stake of 250,484 shares — an estimated $1.85M sold.

Driehaus Capital Management first reported a position in ACRS in Q3 2016 and held it in 10 quarters. The position peaked at $12.9M in Q4 2017. 95 funds tracked by Wall St. Rank hold ACRS as of Q1 2019.

  • Driehaus Capital Management reported no remaining Aclaris Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Driehaus Capital Management sold 250,484 Aclaris Therapeutics shares in Q1 2019, an estimated $1.85M.
  • Driehaus Capital Management first reported a position in Aclaris Therapeutics in Q3 2016 and held it in 10 quarters.
  • Driehaus Capital Management's Aclaris Therapeutics position peaked at $12.9M in Q4 2017.
  • 95 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2019.

Based on Driehaus Capital Management's 13F filing for Q1 2019, filed 15 May 2019.